Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.99
-0.95 (-1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
3 Set-It-and-Forget-It Stocks for Lasting Financial Security
July 02, 2024
Three set-it-and-forget-it stocks powered by consistent growth and sustainable profitability to buy for wealth compounding.
Via
InvestorPlace
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
July 01, 2024
The European Medicines Agency has accepted AstraZeneca's marketing authorization application for sipavibart, an investigational long-acting antibody for pre-exposure prophylaxis of COVID-19 in...
Via
Benzinga
Exposures
COVID-19
7 Biotech Stocks to Boost Your Portfolio to Peak Health
June 26, 2024
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.
Via
InvestorPlace
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
June 26, 2024
China has approved AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy for first-line treatment of locally advanced or metastatic EGFR-mutated non-small cell...
Via
Benzinga
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
June 25, 2024
AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival in early-stage NSCLC. Despite this, Imfinzi's safety profile remains consistent.
Via
Benzinga
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
June 04, 2024
Via
Benzinga
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
June 24, 2024
These are the undervalued pharma stocks and represent companies with a deep research pipeline, that provides sustained growth visibility.
Via
InvestorPlace
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
June 24, 2024
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
June 24, 2024
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare.
Via
InvestorPlace
The 3 Healthiest Healthcare Stocks to Buy for a Huge Dose of Profits
June 23, 2024
Explore three top growth-ready healthcare stocks to buy amid rising demand for healthcare services globally.
Via
InvestorPlace
3 No-Brainer Stocks to Buy for Under $100 Right Now
June 22, 2024
You won't need much money to start investing in these great stocks.
Via
The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
June 18, 2024
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a...
Via
Benzinga
Exposures
COVID-19
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
June 18, 2024
AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints for...
Via
Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
June 17, 2024
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for...
Via
Benzinga
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer
June 17, 2024
AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat advanced forms of endometrial cancer with mismatch repair deficiency. This...
Via
Benzinga
Exposures
Product Safety
3 Best Stocks to Buy From the Fantastic 5
June 17, 2024
Although the best Fantastic 5 stocks offer much relevance and plenty of upside potential, they’re still underappreciated.
Via
InvestorPlace
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer
June 17, 2024
AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymphoma patients over 65.
Via
Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
The companies are closing in on the finish line for two new COPD treatments.
Via
Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Enthusiasm is growing for a looming approval in COPD treatment.
Via
Investor's Business Daily
3 Crazy Good Stocks to Buy With $500 Right Now
June 12, 2024
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.
Via
InvestorPlace
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
June 10, 2024
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services.
Via
Talk Markets
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
June 10, 2024
Five mega companies may offer higher earnings and return potential with lower risk.
Via
Investor's Business Daily
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
June 07, 2024
Discover three of the best must-own stocks, showcasing resilient performance, strategic growth initiatives and consistent dividend payouts.
Via
InvestorPlace
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
June 06, 2024
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside
Via
InvestorPlace
Large Cap BIopharmaceuticals Overview
June 03, 2024
As a defensive play healthcare is weighted at about 12% of the S&P 500.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
June 03, 2024
There's probably a big enough pie here for everyone to get a slice.
Via
The Motley Fool
Stocks Seeing Relentless Buying Pressure; Bonds Are Not
June 02, 2024
Relentless buying pressure, to the degree that we saw in Q4 last year, is evidence of strong underlying demand for stocks. Meanwhile, after a 40-year drawdown, the 50-week rate of change for US 30-year...
Via
Talk Markets
3 No-Brainer Stocks to Buy in June
June 02, 2024
Now is the time to invest in these great stocks.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.